Literature DB >> 11165274

Giardiasis in dairy calves: effects of fenbendazole treatment on intestinal structure and function.

R M O'Handley1, A G Buret, T A McAllister, M Jelinski, M E Olson.   

Abstract

Twelve Giardia duodenalis-infected Holstein dairy calves were allocated into a treatment (n=6) and placebo group (n=6) according to pre-study faecal cyst counts. Calves in the treatment group received an oral dose of 5 mg/kg fenbendazole once daily for 3 days, while placebo calves received a sterile saline solution. Calves were euthanised 7 days following the initiation of treatment and intestinal were collected and prepared for trophozoite quantitation, histology, electron microscopy, and disaccharidase assays. In all calves treated with fenbendazole, intestinal trophozoites were below detection limits, while in saline-treated calves, trophozoites were observed in all intestinal segments. Histologically, no significant difference was observed between treatment groups with respect to intestinal villus height or crypt depth. However, a significant decline in the number of intraepithelial lymphocytes (IEL) was observed in fenbendazole-treated calves when compared with placebo-treated calves in the duodenum (13.9+/-1.2 vs. 17.0+/-1.1 IEL/100 enterocytes) and jejunum (21.6+/-0.8 vs. 30.7+/-1.0 IEL/100 enterocytes). In addition, measurements from TEM micrographs demonstrated a significant increase in microvillus surface area in the jejunum of fenbendazole-treated calves compared with saline-treated calves (31.2+/-10.2 vs. 22.8+/-7.6 microm(2)). This increase in microvillus surface area was also associated with an increase in jejunal maltase activity in fenbendazole-treated calves compared with calves treated with saline. These results demonstrate that fenbendazole is an effective treatment for giardiasis in calves. fenbendazole treatment eliminated Giardia trophozoites from the small intestine of calves resulting in increased microvillus surface area and greater intestinal enzyme activity. This study also demonstrates that the pathogenesis of giardiasis in calves is similar to that observed in humans and laboratory animals, and provides further evidence that Giardia is a pathogen of cattle with potential economic importance.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11165274     DOI: 10.1016/s0020-7519(00)00148-x

Source DB:  PubMed          Journal:  Int J Parasitol        ISSN: 0020-7519            Impact factor:   3.981


  6 in total

1.  The course of experimental giardiasis in Mongolian gerbil.

Authors:  Radka Pecková; Bohumil Sak; Dana Květoňová; Martin Kváč; Eva Koriťáková; Ivona Foitová
Journal:  Parasitol Res       Date:  2018-05-24       Impact factor: 2.289

2.  Synergistic effects of fenbendazole and metronidazole against Giardia muris in Swiss mice naturally infected.

Authors:  Renata Coltro Bezagio; Cristiane Maria Colli; Liara Izabela Lopes Romera; Érika Cristina Ferreira; Ana Lúcia Falavigna-Guilherme; Mônica Lúcia Gomes
Journal:  Parasitol Res       Date:  2016-12-30       Impact factor: 2.289

Review 3.  Behind the smile: cell biology and disease mechanisms of Giardia species.

Authors:  Johan Ankarklev; Jon Jerlström-Hultqvist; Emma Ringqvist; Karin Troell; Staffan G Svärd
Journal:  Nat Rev Microbiol       Date:  2010-04-19       Impact factor: 60.633

4.  The use of a Giardia vaccine as an immunotherapeutic agent in dogs.

Authors:  M E Olson; C J Hannigan; P F Gaviller; L A Fulton
Journal:  Can Vet J       Date:  2001-11       Impact factor: 1.008

5.  Severe weight loss in lambs infected with Giardia duodenalis assemblage B.

Authors:  Fabio Aloisio; Giovanni Filippini; Pietro Antenucci; Elvio Lepri; Giovanni Pezzotti; Simone M Cacciò; Edoardo Pozio
Journal:  Vet Parasitol       Date:  2006-08-07       Impact factor: 2.738

6.  Efficacy of vaccination in preventing giardiasis in calves.

Authors:  Fabienne D Uehlinger; Ryan M O'Handley; Spencer J Greenwood; Nicole J Guselle; Leslie J Gabor; Cecilia M Van Velsen; Robert F L Steuart; Herman W Barkema
Journal:  Vet Parasitol       Date:  2007-03-12       Impact factor: 2.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.